Background: Rheumatoid arthritis (RA) is a chronic autoimmune disorder affecting joint health and patients' overall well-being. While methotrexate (MTX) is a standard therapeutic intervention, enhancing its efficacy with pain-specific nursing remains underexplored.
Objective: This study aims to assess the impact of combining MTX with pain-specific nursing on patients with RA, providing valuable insights for clinical practice and offering an improved therapeutic approach to alleviate pain and enhance the overall quality of life for affected individuals.
Methods: We conducted a prospective cohort study, choosing a cohort of 86 RA patients admitted to our hospital from March 2021 to March 2023. After treatment, we compared the number of swollen and painful joints, duration of morning stiffness, and scores on the Visual Analogue Scale (VAS), Pittsburgh Sleep Quality Index (PSQI), and Self-rating Anxiety Scale/Self-rating Depression Scale (SAS/SDS) between the two groups. Nursing satisfaction was surveyed upon discharge, and patient quality of life was assessed using the 36-item Short Form Health Survey (SF-36).
Results: The research group exhibited a notable decrease in the number of swollen and painful joints, significantly shorter morning stiffness duration, and marked reductions in VAS, PSQI, SAS, and SDS scores compared to the control group (P < .05). Additionally, nursing satisfaction and SF-36 scores were higher in the research group (P < .05).
Conclusions: The combination of MTX and pain-specific nursing effectively alleviated pain and improved the quality of life and nursing satisfaction among RA patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Evaluation of a peer support group programme for vulnerable host population and refugees living with diabetes and/or hypertension in Lebanon: a before-after study.
Confl Health
January 2025
London School of Hygiene and Tropical Medicine, Department of Non-Communicable Diseases Epidemiology, Keppel street, London, WC1E 7HT, UK.
Background: Non-communicable diseases (NCDs) are the leading cause of death globally, and many humanitarian crises occur in countries with high NCD burdens. Peer support is a promising approach to improve NCD care in these settings. However, evidence on peer support for people living with NCDs in humanitarian settings is limited.
View Article and Find Full Text PDFThe PROPHECI trial: a phase II, double-blind, placebo-controlled, randomized clinical trial for the treatment of pseudoxanthoma elasticum with oral pyrophosphate.
Trials
January 2025
Université Côte d'Azur, CNRS, LP2M, Nice, France.
Background: /aims. Pseudoxanthoma Elasticum (PXE, OMIM 264800) is an autosomal, recessive, metabolic disorder characterized by progressive ectopic calcification in the skin, the vasculature and Bruch's membrane. Variants in the ABCC6 gene are associated with low plasma pyrophosphate (PPi) concentration.
View Article and Find Full Text PDFDetection of early relapse in multiple myeloma patients.
Cell Div
January 2025
Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Background: Multiple myeloma (MM) represents the second most common hematological malignancy characterized by the infiltration of the bone marrow by plasma cells that produce monoclonal immunoglobulin. While the quality and length of life of MM patients have significantly increased, MM remains a hard-to-treat disease; almost all patients relapse. As MM is highly heterogenous, patients relapse at different times.
View Article and Find Full Text PDFNeurocognitive impact of different irradiation modalities for patients with grade I-II skull base meningioma: a prospective multi-arm cohort study (CANCER COG).
Radiat Oncol
January 2025
ISTCT UMR 6030-CNRS, Université de Caen-Normandie, Caen, France.
Background: Radiotherapy as a complement or an alternative to neurosurgery has a central role in the treatment of skull base grade I-II meningiomas. Radiotherapy techniques have improved considerably over the last two decades, becoming more effective and sparing more and more the healthy tissue surrounding the tumour. Currently, hypo-fractionated stereotactic radiotherapy (SRT) for small tumours and normo-fractionated intensity-modulated radiotherapy (IMRT) or proton-therapy (PT) for larger tumours are the most widely used techniques.
View Article and Find Full Text PDFStatistical analysis plan for a pragmatic randomised controlled trial comparing enhanced acceptance and commitment therapy plus ( +) added to usual aftercare versus usual aftercare only, in patients living with or beyond cancer: SUrvivors' Rehabilitation Evaluation after CANcer (SURECAN) trial.
Trials
January 2025
London Centre for Primary Care, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
Background: The aim of the SURECAN trial is to evaluate a person-centred intervention, based on Acceptance and Commitment Therapy (ACT Plus ( +)), for people who have completed treatment for cancer with curative intent, but are experiencing poor quality of life. We present the statistical analysis plan for assessing the effectiveness and cost-effectiveness of the intervention in improving quality of life 1 year post randomisation.
Methods And Design: SURECAN is a multi-centre, pragmatic, two-arm, partially clustered randomised controlled superiority trial comparing the effectiveness of ACT + added to usual care with usual aftercare.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!